Redhill Biopharma
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 113
- Market Cap
- $9.6M
- Website
- http://www.redhillbio.com
- Introduction
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the...
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
- Conditions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 61
- Registration Number
- NCT04723537
- Locations
- 🇺🇸
University Hospitals Cleveland, Cleveland, Ohio, United States
🇺🇸Southwest Family Medicine Research, Dallas, Texas, United States
🇿🇦Langeberg Medical Centre - Clinical Trials, Kraaifontein, Cape Town, South Africa
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 125
- Registration Number
- NCT04616924
- Locations
- 🇺🇸
Medical Facility, Wauwatosa, Wisconsin, United States
🇺🇸Medical Facility 1, Orlando, Florida, United States
🇺🇸Medical Facility 2, Orlando, Florida, United States
Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- RedHill Biopharma Limited
- Registration Number
- NCT04502069
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 475
- Registration Number
- NCT04467840
- Locations
- 🇬🇧
ABC-201 Site 251, Gillingham, United Kingdom
🇷🇺ABC-201 Site 104, Tver, Russian Federation
🇧🇷ABC-201 Site 403, São Paulo, Brazil
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 42
- Registration Number
- NCT04414618
- Locations
- 🇺🇸
Memorial Hermann, Memorial City Medical Center, Houston, Texas, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇮🇱Ziv Medical Center, Safed, Israel
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 142
- Registration Number
- NCT04027894
Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
- Conditions
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 142
- Registration Number
- NCT04026984
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- RedHill Biopharma Limited
- Registration Number
- NCT03414489
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 65
- Registration Number
- NCT03377179
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- RedHill Biopharma Limited
- Target Recruit Count
- 455
- Registration Number
- NCT03198507
- Locations
- 🇺🇸
Research Site, Lynchburg, Virginia, United States
🇺🇸Research Center, Houston, Texas, United States
🇺🇸Research site, Milwaukee, Wisconsin, United States